Galectin-7 in lymphoma: Elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model

Cancer Research

Volumn 67, Issue 6, 2007, Pages 2824-2829

  Demers, Melanie ^a   Biron Pain, Katherine ^a   Hébert, Josée ^b   Lamarre, Alain ^a   Magnaldo, Thierry ^c   St Pierre, Yves ^a  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GALECTIN 7; GELATINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EXPERIMENTAL MODEL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOMA; LYMPHOMA CELL; METASTASIS; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL LINE, TUMOR; DOWN-REGULATION; GALECTINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA; MATRIX METALLOPROTEINASE 9; RNA, ANTISENSE; TRANSFECTION;

EID: 34047256445     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3891     Document Type: Article

References (33)

1. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807-10.
2. Henrick K, Bawumia S, Barboni EA, Mehul B, Hughes RC. Evidence for subsites in the galectins involved in sugar binding at the nonreducing end of the central galactose of oligosaccharide ligands: sequence analysis. homology modeling, and mutagenesis studies of hamster galectin-3. Glycobiology 1998;8:45-57.
3. Barboni EA, Bawumia S, Henrick K, Hughes RC. Molecular modeling and mutagenesis studies of the N-terminal domains of galectin-3: evidence for participation with the C-terminal carbohydrate recognition domain in oligosaccharide binding. Glycobiology 2000;10:1201-8.
4. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2004;19:527-35.
5. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995;378:736-9.
6. Chung CD, Patel VP, Moran M, Lewis LA, Miceli MC. Galectin-1 induces partial TCR ζ-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 2000;165:3722-9.
7. Walzel H, Blach M, Hirabayashi J, Kasai KI, Brock J. Involvement of CD2 and CD3 in galectin-1 induced signaling in human Jurkat T-cells. Glycobiology 2000;10: 131-40.
8. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001;409:733-9.
9. Kasai K, Hirabayashi J. Galectins: a family of animal lectins that decipher glycocodes. J Biochem (Tokyo) 1996;119:1-8.
10. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29-41.
11. Madsen P, Rasmussen HH, Flint T, et al. Cloning, expression, and chromosome mapping of human galectin-7. J Biol Chem 1995;270:5823-9.
12. Lu J, Pei H, Kaeck M, Thompson, HJ. Gene expression changes associated with chemically induced rat mammary carcinogenesis. Mol Carcinog 1997;20:204-15.
13. Rorive S, Eddafali B, Fernandez S, et al. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol 2002;15:1294-301.
14. Moisan S, Demers M, Mercier J, Magnaldo T, Potworowski EF, St-Pierre Y. Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype. Leukemia 2003;17: 751-9.
15. Lalancette M, Aoudjit F, Potworowski EF, St-Pierre Y. Resistance of ICAM-1-deficient mice to metastasis overcome by increased aggressiveness of lymphoma cells. Blood 2000;95:314-9.
16. Bernerd F, Sarasin A, Magnaldo T. Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocytes. Proc Natl Acad Sci U S A 1999;96:11329-34.
17. St John JA, Key B. Expression of galectin-1 in the olfactory nerve pathway of rat. Brain Res Dev Brain Res 1999;117:171-8.
18. Tenne-Brown J, Puche AC, Key B. Expression of galectin-1 in the mouse olfactory system. Int J Dev Biol 1998;42:791-9.
19. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
20. Demers M, Magnaldo T, St-Pierre Y. A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression. Cancer Res 2005;65:5205-10.
21. Daniels MA, Hogquist KA, Jameson SC. Sweet 'n' sour: the impact of differential glycosylation on T cell responses. Nat Immunol 2002;3:903-10.
22. Allione A, Wells V, Forni G, Mallucci L, Novelli F. β-Galactoside- binding protein (βGBP) alters the cell cycle, up-regulates expression of the α- and β-chains of the IFN-γ receptor, and triggers IFN-γ-mediated apoptosis of activated human T lymphocytes. J Immunol 1998;161: 2114-9.
23. Sturm A, Lensch M, Andre S, et al. Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol 2004;173:3825-37.
24. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996;56:5279-84.
25. Saussez S, Cucu DR, Decaestecker C, et al. Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol 2006;13:999-1009.
26. Kossakowska AE, Urbanski SJ, Huchcroft SA, Edwards DR. Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. Oncol Res 1992;4:233-40.
27. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas, and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 1996;73: 1401-8.
28. Ostergaard M, Rasmussen HH, Nielsen H, et al. Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res 1997;57:4111-7.
29. Kuwabara I, Kuwabara Y, Yang, RY et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem 2002;277:3487-97.
30. Kopitz J, Andre S, von Reitzenstein C, et al. Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene 2003;22:6277-88.
31. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
32. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006;1760:616-35.
33. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389: 300-5.